Short Communication
Letter to Editor
UCSF Benioff Children's Hospital Oakland
Julie D Saba*
Department of Pediatric Cancer, University of California, USA
*Corresponding author: Julie D Saba, Department of Pediatric Cancer, University of California, USA
Published: 19 Jun, 2017
Cite this article as: Saba JD. UCSF Benioff Children's
Hospital Oakland. Clin Oncol. 2017; 2:
1306.
Letter to Editor
As a pediatric oncologist, I cared for many patients who were cured as a result of their
participation in nationwide cooperative clinical trials. Due to the rarity of childhood cancer,
cooperative clinical trials offered the only way to recruit sufficient numbers of patients for each trial
in a timely manner. This cooperative approach catapulted the overall survival rate for childhood
cancer from 10% to nearly 90% in forty years.
Cancer incidence is much higher in adults than in children. Due to the abundance of cancer
patients, institution--based trials have been the norm. However, this practice is not efficient and has
resulted in a barrier to access, limiting trial participants to residents living within the vicinity of the
trial centers and patients who have sufficient financial resources to travel.
We are at the threshold of a new era in cancer treatment, with breakthrough therapeutics
emerging on a regular basis. I believe it is time to address the inefficiency and social injustice
inherent in regionally restricted clinical trials. Toward that end, I propose the formation of a
National Organization of Cooperative Clinical Adult Oncology Trials (NOCCAOT) paid for by the
National Institutes of Health and the Cancer Moonshot Program.